medigraphic.com
Colegio de Medicos y Cirujanos República de Costa Rica

2015, Number 617

<< Back Next >>

Rev Med Cos Cen 2015; 72 (617)

Miocardiopatía periparto

Díaz CJ, Bogantes LP

Language: Spanish
References: 50
Page: 759-767
PDF size: 513.55 Kb.


ABSTRACT

Postpartum cardiomyopathy is a rare heart condition that occurs during the last month pregnancy’s and postpartum five months with a early and late manifestation of the same pathology, characterized by heart failure, dilated left chambers, ejection fraction below 45% in women without prior history. We report a case of a patient of 28 years old, multiparty, two previous ante partum death, 33.2 gestation’s weeks, anti phospholipid syndrome than 6 years of evolution that’s enters emergency, with dyspnea of small efforts, jugular engorgement, 45 degrees, NYHA III, lefh bundle branch block, dilated left chambers and ejection fraction of 35%, started treatment for hemodynamic stabilization of the patient and steroid treatment, at 34 weeks was performed cesarean for higth fetal risk, and was born masculine product alive, restricted in a very good condition and a mothers without surgical complications, patient with clinical improvement is discharged in strict control of cardiology.


REFERENCES

  1. Abbas AE, Lester SJ, Connolly H. Pregnancy and cardiovascular system. Int J Cardiol 2005;98:179-89.

  2. Abboud J, Murad Y, Chen-Scarabelli C, et al. Peripartum cardiomyopathy: a comprehensive review. Int J Cardiol 2007;118;3:295-303.

  3. Adams JW, Sakata Y, Davis MG, Sah VP, Wang Y, Liggett SB, et al. Enhanced Gaq signaling: A common pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc Natl Acad Sci 1998;95:10140-10145.

  4. Blanco,F et al participacion de la prolactina en la respuesta immune. Bol Med Hosp Infant Mex 2012;69(5):329-336

  5. Brown CS, Bertolet BD. Peripartum cardiomyopathy: a com- prehensive review. Am J Obstet Gynecol 1998;178:409-414.

  6. Bultmann BD, Klingel K, Nabauer M, Wallwiener D, Kandolf R. High prevalence of viral genomes and inflammation in peripar- tum cardiomyopathy. Am J Obstet Gynecol 2005;193:363-5.

  7. Cenac A, Djibo A. Postpartum cardiac failure in Sudanese-Sahelian Africa: clinical prevalence in western Niger. Am J Trop Med Hyg 1998;58:319-23.

  8. Corbacho AM, Martinez De La Escalera G, Clapp C. Roles of prolactin and related members of the prolactin/growth hor- mone/placental lactogen family in angiogenesis. J Endocrinol 2002;173:219-238.

  9. Demakis, John et al Peripartum Cardiomyopathy Circulation. 1971,44:964-968.

  10. Diao M, Diop IB, Kane A, Camara S, Kane A, Sarr M, Ba SA, Diouf SM. Electro- cardiographic recording of long duration (Holter) of 24 hours during idiopathic cardiomyopathy of the peripartum. Arch Mal Coeur Vaiss 2004;97:25–30.

  11. Eghbali M, Deva R, Alioua A, et al. Molecular and functional signature of heart hypertrophy during pregnancy. Circ Res 2005;96:1208-1216.

  12. Elkayam, Uri, Mohammed, W, et al Pregnancy- Associated Cardiomyopayhy. Clinical Characteristics and a Comparision Between Early and Late Presentation. Circulation 2005;111:2050-2055.

  13. Ferreira, Carla, Silva, Joana, et al. Cardiomiopatia periparto: A proposito de uncaso clinicoARQUIVOS DE MEDICINA, 2014;28(3):64-67.

  14. Fett JD, Carraway RD, Dowell DL, King ME, Pierre R. Peripartum cardiomyopathy in the Hospital Albert Schweitzer District of Haiti. Am J Obstet Gynecol 2002;186:1005-10.

  15. Fett JD, Christie LG, Carraway RD, Murphy JG. Five-year prospective study of the incidence and prognosis of peripar- tum cardiomyopathy at a single institution. Mayo Clin Proc 2005;80:1602-6.

  16. Gleicher N. Why much of the pathophysiology of preeclamp- siaeclampsia has to be autoimmune in nature. Am J Obstet Gynecol 2007;196:5.e1-7.

  17. Gleicher N, and Elkayam U. Peripartum cardiomyopathy, an autoimmune manifestation of allograft rejection? Autoimmunity Reviews2009;8:384-387.

  18. Gonzalez C, Corbacho AM, Eiserich JP, et al. 16K-prolactin inhibits activation of endothelial nitric oxide synthase, intracellular calcium mobilization, and endotheliumdependent vasorelaxation. Endocrinology 2004;145:5714-5722.

  19. Hayakawa Y, Chandra M, Miao W, et al. Inhibition of cardiac myocyte apoptosis improves cardiac function and abolishes mortality in the peripartum cardiomyopathy of G alpha(q) transgenic mice. Circulation 2003;108:3036-3041.

  20. Hernandez, A et al Cardiomiopatia periparto: reporte de un caso clinico y revision de la literature. Revista Colombiana de ginecologia y obstetrician . vol 60 No. 3 2009(294-299).

  21. Heims AK, Kittner SJ. Pregnancy and stroke. CNS Spectr 2005; 10: 580-587

  22. Hilfiker-Kleiner D et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 2007; 128: 589-600.

  23. Hilfiker-Kleiner D, Kaminski K, Podewski E, Bonda T, Schaefer A, Sliwa K, Forster O, Quint A, Landmesser U, Doerries C, Luchtefeld M, Poli V, Schneider MD, Balligand JL, Desjardins F, Ansari A, Struman I, Nguyen NQ, Zschemisch NH, Klein G, Heusch G, Schulz R, Hilfiker A, Drexler H. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 2007;128:589– 600.

  24. Hilfiker-Kleiner D, Meyer GP, Schieffer E, et al. Recovery from postpartum cardiomyopathy in 2 patients by blocking prolactin release with bromocriptine. J Am Coll Cardiol 2007;50:2354-2355.

  25. Hilfiker-Kleiner D, Kaminski K, Podewski E, et al. A cathepsin D-cleaved 16-kDa form of prolactin mediates postpartum cardiomyopathy. Cell 2007;128:589-600.

  26. Hilfiker-Kleiner D, Meyer GP, Schieffer E, et al. Recovery from postpartum cardiomyopathy in 2 patients by blocking prolactin release with bromocriptine. J Am Coll Cardiol 2007;50:2354-2355.

  27. Horseman ND, Zhao W, Montecino Rodriguez E, Tanaka M, Nakashima K, Engle SJ, et al. Defective mammopoiesis, but normal hematopoiesis, in mice with target disruption of the prolactine gene. EMBO J 1997;16:6926-6935.

  28. Hunt SA, et al. ACC/AHA 2005 Guideline Update for the diagnosis and management of chronic heart failure in the adult. Circulation 2005; 112: 1825- 1852.

  29. Johnson-Coyle, Jensen L,Sobey A. Peripartum cardiomyopathy: review and practice guidelines. Am J Crit Care 2012;21(2):89-98

  30. Lampert MB, Lang RM. Peripartum cardiomyopathy. Am Heart J 1995;130: 860 – 870.

  31. Lamparter S, Pankuweit S, Maisch B. Clinical and immunologic characteristics in peripartum cardiomyopathy. Int J Cardiol 2007;118:14-20.

  32. Lang CT, King JC. Maternal mortality in the United States. Best Pract Res Clin Obstet Gynaecol 2008;22:517-31.

  33. Lang RM, Lampert MB, Poppas A, et al. En: Elkayam U, Gleicher N, editors. Cardiac problem in pregnancy: diagnosis and management of maternal and fetal disease. 3rd Ed. New York: Wiley-Liss; 1998. p.87.

  34. Mann DL. Stress activated cytokines and the heart: from adaptation to maladaptation. Cytokine Growth Factor Rev 1996;7:341-54.

  35. McNamara DM, Holubkov R, Starling RC, et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation 2001; 103: 2254-2259

  36. Murali S, Baldisseri MR. Peripartum cardiomyopathy. Crit Care Med 2005; 33 (suppl): S340-46.

  37. Paulus WJ. How are cytokines activated in heart failure? Eur J Heart Fail 1999;100:999-1008.

  38. Pearson GD, Veille JC, Rahimtoola S, et al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and office of rare diseases (National Institute of Health) workshop recomendations and review. JAMA 2000;283(9):1183-8.

  39. Phillips SD, Warnes CA. Peripartum cardiomyopathy: current therapeutic perspectives. Curr Treat Options Cardiovasc Med 2004; 6: 481-488.

  40. Platzbecker U, Klingel K, Thiede C, Freiberg-Richter J, Schuh D, Ehninger G, et al. Acute heart failure after allogeneic blood stem cell transplantation due to massive myocardial infiltration by cytotoxic T cells of donor origin. Bone Marrow Transplant 2001;27:107-9.

  41. Pritchard JA. Changes in the blood volume during pregnancy and delivery. Anesthesiology 1965;26:393-399.

  42. Qasqas SA, McPherson C, Frishman WH, et al. Cardiovascular pharmacotherapeutic consideration during pregnancy and lactation. Cardiol Rev 2004;12:201-221, 240-260.

  43. Ro, A, and Frishman, WH. Peripartum Cardiomyopathy. Cardiology in Review 2006;14:35-42.

  44. Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail 2010;12(8):767-78.

  45. Sliwa K, Hilfiker- Kleiner et al EURObservational Research Programme: a worldwide registry on peripartum cardiomyopathy (PPCM) in conjunction with the Heart Failure Association of the European Society of Cardiology Working Group on PPCM European Journal of Heart Failure (2014) 16, 583–591

  46. Sliwa K, Fett J, Elkayam U. Peripartum cardiomyopathy. Lancet 2006;368:687–693.

  47. Sundstrom JB, Fett JD, Carraway RD, Ansari AA. Is peripar- tum cardiomyopathy an organ-specific autoimmune disease? Autoimmun Rev 2002;1:73-7.

  48. Toescu V, Nuttall SL, Martin U, Kendall MJ, Dunne F. Oxidative stress and normal pregnancy. Clin Endocrinol (Oxf) 2002;57:609–613.

  49. Velasquez, J, Duque, M, cardiomiopatia periparto. Revista colombiana de cardiologia 2008;15:5-11.

  50. Wilansky S, Reuss CS, and Willerson JT. Pregnancy and the Heart. In: Willerson JT, Wellens HJJ, Cohn JN, Hol- mes DR Jr. Cardiovascular Medicine. London: Springer. 2007;116:2453-2483.




2020     |     www.medigraphic.com